# [18F]PBR111 and Microglial Activation in Multiple Sclerosis

> **NCT01428505** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 50 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **RADIATION:** [18F]PBR111

## Key facts

- **NCT ID:** NCT01428505
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** The Study was terminated because there was insufficient data to complete the study objectives
- **Last updated:** 2016-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01428505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01428505, "[18F]PBR111 and Microglial Activation in Multiple Sclerosis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01428505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*